VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology

M-CSF Potently Augments RANKL-Induced Resorption Activation in Mature Human Osteoclasts

(2011) Jason M. Hodge et al.   PLoS One

Anti-Placental Growth Factor Reduces Bone Metastasis by Blocking Tumor Cell Engraftment and Osteoclast Differentiation

(2010) L. Coenegrachts et al.   CANCER RESEARCH

Rapid publication: Impairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op Mouse

(2010) R. Felix et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis

(2010) Marc Baud'Huin et al.   JOURNAL OF PATHOLOGY

Histogenetic Characterization of Giant Cell Tumor of Bone

(2008) Manuela Salerno et al.   CLINICAL ORTHOPAEDICS AND RELATED RESEARCH

VEGF-C, a Lymphatic Growth Factor, Is a RANKL Target Gene in Osteoclasts That Enhances Osteoclastic Bone Resorption through an Autocrine Mechanism

(2008) Qian Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte–osteoclast differentiation via induction of VEGF

(2008) HJ Knowles et al.   JOURNAL OF PATHOLOGY

Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome

(2008) H. Lin et al.   SCIENCE

Expression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell Tumors

(2006) Gerald J. Atkins et al.   JOURNAL OF BONE AND MINERAL RESEARCH